Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0160

Scientific exchange · Dr. Daniel Weber

16 Apr 2026 · Phone · Dr. Daniel Weber, Royal Marsden · MSL Dr. Anna Becker · Nephrada

ReviewedVeeva CRMENG-0160—

Capture insight from this engagement

Location: Royal Marsden
Therapeutic area: Nephrology
Country: United Kingdom
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

Patient-reported outcomes
Proteinuria as surrogate endpoint

Scientific content used

Surrogate-endpoint evidence review
NPH mechanism-of-action deck

Questions raised

No questions recorded.

Notes

Scientific exchange with community nephrologist at Royal Marsden. Discussed patient-reported outcomes, proteinuria as surrogate endpoint.

Insights captured (1)

Capture insight

INS-0007Low
Patient-reported outcomes
Patient-reported outcomes: practice variation observed reported by community nephrologist (GB).
Closed

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Invite to advisory board

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 5
Depth of exchange: 4
Actionability: 1

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0160

Audit history (0)

All create, update and approval events for this record

No audit events in sample data